HSPA9 and cancer: Mortalin enhances the expression levels of mesenchymal markers (vimentin, fibronectin, and β-catenin), while downregulating the expression levels of epithelial markers (E-cadherin, CK8, and CK18), contributing to epithelial–mesenchymal transition and cancer metastasis.